Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation

Journal of Neuroimmunology

Volumn 92, Issue 1-2, 1998, Pages 113-121

  Miller, Ariel ^a,b   Shapiro, Sarah ^a   Gershtein, Rosa ^a   Kinarty, Amalia ^a   Rawashdeh, Hanna ^a   Honigman, Silvia ^a,b   Lahat, Nitza ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bystander suppression; Copolymer 1; Copolymer 1; Cytokines; Immunomodulation; Multiple sclerosis; Th1 Th2

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADULT; DISABLED PERSONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; PEPTIDES; RECEPTORS, INTERLEUKIN-2; RECURRENCE; SOLUBILITY; TH1 CELLS; TH2 CELLS;

EID: 0032427976     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00191-X     Document Type: Article

References (64)

1. Abramsky O., Teitelbaum D., Arnon R. Effect of a synthetic polypeptide (Copolymer 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: preliminary report. J. Neurol. Sci. 31:1977;433-438.
2. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 94:1997;10821-10826.
3. Antel J.P., Owens T. The attraction of adhesion molecules. Ann. Neurol. 34:1993;123-124. [editorial].
4. Antel J.P., Bania M.B., Reder A., Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137:1986;137-141.
5. Arnon R., Sela M., Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J. Neurol. 243:1996;S8-13.
6. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., Kerlero de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG induced disease. J. Neurol. 243:1996;S14-22.
7. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler, Keilson M., Merria M., Wassertheil-Smollerer S., Spada V., Arnon R., Jackobsohn I., Teitelbaum D., Sela M. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317:1987;408-414.
8. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis. Ann. Neurol. 37:1995;424-435.
9. Cannella B., Gao Y.L., Brosman C., Raine C.S. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J. Neurosci. Res. 45:1996;735-746.
10. Cua D.J., Hinton D.R., Kirkman L., Stohlman S.A. Macrophages regulate induction of delayed-type hypersensitivity and experimental allergic encephalomyelitis in SJL mice. Eur. J. Immunol. 25:1995;2318-2324.
11. Fabry Z., Topham D.J., Fee D., Herlein J., Carlino J.A., Hart M.N., Sriram S. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J. Immunol. 155:1995;325-332.
12. Falcone M., Bloom B.R. A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J. Exp. Med. 185:1997;901-907.
13. Fridkis-Hareli M., Teitelbaum D., Gurevitch E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells - specificity and promiscuity. Proc. Natl. Acad. Sci. USA. 91:1994;4872-4876.
14. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linington C., Raine C.S., Hauser S.L. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
15. Hafler D.A., Weiner H.L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144:1995;75-107.
16. Hartung H.P., Reiners K., Archelos J.J., Michels M., Seeldrayers P., Heidenreich F., Pflughaupt K.W., Toyka K.Y. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:1995;186-193.
17. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulation in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 40:1990;1735-1739.
18. Hofmann F.M., Hinton D.R., Johnson K., Merrill J.E. Tumor necrosis factor identified in multiple sclerosis. J. Exp. Med. 170:1980;607-612.
19. IFNβ multiple sclerosis study group, 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
20. Inobe J.I., Chen Y., Weiner H.L. In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis. Ann. N.Y. Acad. Sci. 778:1996;390-392.
21. Jacobs L., Cookfair D., Rudick R., Hemdon R., Richert J., Salazar A. Results of phase III trial of intramuscular recombinant beta interferon as treatment of multiple sclerosis. Ann. Neurol. 36:1994;256-262.
22. Johns L.D., Flanders K.C., Ranges G.E., Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147:1991;1792-1796.
23. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.S. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 45:1995;1268-1276.
24. Karin N., Mitchell D.J., Brocke S., Ling N., Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180:1994;2227-2237.
25. Karussis D.M., Meiner Z., Lehmann D., Schwarz A., Gomori M., Linde A., Abramsky O. Immunomodulation of experimental autoimmune encephalomyelitis (EAE and CR-EAE) and of multiple sclerosis with quinoline-3-carboxamide. Neurology. 47:1996;341-346.
26. Kennedy J.K., Torrance D.S., Picka K.S., Mahler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
27. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1993;1444-1452.
28. Kuruvilla A.P., Shah R., Hochwald G.M., Liggitt H.D., Palladino M.A., Thorbecke G.J. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88:1991;2918-2921.
29. Lafaille J.J., Van de Keere F., Hsa A.L., Baron J.L., Haas W., Reine C.S., Tanagawa S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186:1997;307-312.
30. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
31. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
32. Merrill J.E., Storm S.R., Ellison G.W., Myers L.W. In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunol. 9:1989;84-96.
33. Miller A., Lider O., Weiner L.H. Antigen driven bystander suppression after oral administration of antigens. J. Exp. Med. 174:1991;791-798.
34. Milo R., Panitch H.S. Additive effects of copolymer 1 and interferon Beta-1b on the immune responses to myelin basic protein. J. Neuroimmunol. 61:1995;185-193.
35. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., Grob D. Defective production of anti-inflammatory cytokine TGF-beta by T cell lines from patients with active multiple sclerosis. J. Immunol. 152:1994;6003-6010.
36. Mosmann T.R., Coffman R.L. Two types of mouse helper T cell clone: implications for immune regulation. Immunol. Today. 8:1987;223-227.
37. MS/MRI study group, Paty D.W. The IFNβ multiple sclerosis study group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis of multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
38. Pitzalis C., Sharrack B., Gray I.A., Lee A., Hughes R.A. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J. Neuroimmunol. 74:1997;62-68.
39. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtelotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
40. Pozzilli C., Bastianello S., Koudriavtseva T., Gasperini C., Bozzao A., Millefiorini E., Galgani S., Buttinelli C., Perciaccante G., Piazza G., Bozzao L., Fieschi C. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 61:1996;251-258.
41. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146:1991;3012-3017.
42. Racke M.K., Martin R., McFarland H., Fritz R.B. Copolymer 1-induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J. Neuroimmunol. 37:1992;75-84.
43. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
44. Racke M.K., Burnett D., Pak S.H., Albert P.S., Cannella B., Raine C.S., McFarlin D.E., Scott D.E. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J. Immunol. 154:1995;450-458.
45. Rieckmann P., Martin S., Weichselbraun I., Albrechet M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: sICAM-1 is an indicator for relapse. Neurology. 44:1994;2367-2372.
46. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Borner T., Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64:1996;193-200.
47. Rudick R.A., Ransohoff R.M. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch. Neurol. 49:1992;265-270.
48. Sharief M.K., Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325:1991;467-472.
49. Sharief M.K., Noori M.A., Ciardi M., Cirelli A., Thompson E.J. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: correlation with TNF-α and blood-brain barrier damage. J. Neuroimmunol. 43:1993;15-22.
50. Steinman L., Miller A., Bernard C.C.A., Oxsenberg J.R. The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy. Annu. Rev. Neurosci. 17:1994;247-265.
51. Steinman L., Waisman A., Altmann D. Major T-Cell responses in multiple sclerosis. Molecular Medicine Today. 1:1995;79-83.
52. Street N.E., Schumacher J.H., Fong T.H., Bass H., Fiorentino D.F., Leverah J.A., Mosmann T.R. Heterogeneity of mouse helper T cells: evidence from bulk culture and limiting dilution cloning for precursors of Th1 and Th2 cells. J. Immunol. 144:1990;1629-1639.
53. Teitelbaum D., Milo R., Arnon R., Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific factor myelin basic protein. Proc. Natl. Acad. Sci. USA. 898:1992;137-141.
54. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell response. J. Neuroimmunol. 64:1996;209-217.
55. Teitelbaum D., Arnon R., Sela M. Copolymer 1: from basic research to clinical application. Cell Mol. Life Sci. 53:1997;24-28.
56. Trotter J.L., Collins K.G., van der Veen R.C. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. J. Neuroimmunol. 33:1991;29-36.
57. van der Laan L.J., Ruuls S.R., Weber K.S., Lodder I.J., Dopp E.A., Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 70:1996;145-152.
58. 2 cells with related peptide specificity, relative roles of IL-4 and IL-10. J. Neuroimmunol. 48:1993;213-217.
59. Vandenbark A.A., Chou Y.K., Whitham R., Mass M., Buenafe A., Liefeld D., Kavanagh D., Cooper S., Hashim G.A., Offner H., Bourdette D.N. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 2:1996;1109-1115.
60. Voshuhl R.R., Martin R., Bergman C., Dalal M., Ruddle N.H., McFarland H.F. T helper (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity. 15:1993;137-143.
61. Waisman A., Ruiz P.J., Hirschberg D.L., Gelman A., Oksenberg J.R., Brocke S., Mor F., Cohen I.R., Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents auto-immune encephalomyelitis and activates Th2 immunity. Nat. Med. 8:1996;899-905.
62. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today. 18:1997;335-343.
63. Weller R.O., Engelhardt B., Philips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathology. 6:1996;275-288.
64. Windhagen A., Nicholson L.B., Weiner H.L., Kuchroo V.K., Hafler D.A. Role of Th1 and Th2 cells in neurologic disorders. Chem. Immunol. 63:1996;171-186.